Gossamer Bio Change in Accounts Receivable 2017-2025 | GOSS

Gossamer Bio change in accounts receivable from 2017 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Gossamer Bio Change in Accounts Receivable 2017-2025 | GOSS

Gossamer Bio change in accounts receivable from 2017 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$243.4B
Amgen (AMGN)$156.3B
Gilead Sciences (GILD)$147.7B
Vertex Pharmaceuticals (VRTX)$100.1B
Bristol Myers Squibb (BMY)$97.3B
CSL (CSLLY)$85B
GSK (GSK)$80B
Regeneron Pharmaceuticals (REGN)$60B
Alnylam Pharmaceuticals (ALNY)$58B
Argenex SE (ARGX)$39.9B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$27B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.4B
Genmab (GMAB)$14.7B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.5B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8B
Halozyme Therapeutics (HALO)$7.7B